SNSE — Sensei Biotherapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1829802 ·
Last close
$14.53
Market Cap
$19.50M
52W High
$36.07
52W Low
$10.78
ADV30
48,093
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -170,627,000 | -170,236,000 | 205,381,000 | 152,325,000 | 342,667,000 |
| Dec 2025 | 0 | — | -4,957,000 | -4,717,000 | 22,902,000 | 8,668,000 | 4,310,000 |
| Sep 2025 | 0 | — | -4,851,000 | -4,569,000 | 27,589,000 | 10,562,000 | 4,582,000 |
| Jun 2025 | 0 | — | -5,206,000 | -4,936,000 | 31,783,000 | 12,557,000 | 4,469,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-24,092,000
Investing CF
$-18,855,000
Financing CF
$185,395,000
CapEx
$-6,000
Dividends Paid
—
Buybacks
$-15,146,000
EPS Diluted TTM
$-144.38
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-453,373,000
Inventory
—
Receivables
—
ST Investments
$50,468,000
EBIT TTM
$-184,830,000
Pretax Income TTM
$-184,458,000
Interest Exp TTM
$32,000
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -22,288,000 | -21,085,000 | 22,902,000 | 4,310,000 | — | -20,453,000 |
| Dec 2024 | 0 | -31,663,000 | -30,157,000 | 45,361,000 | 6,975,000 | — | -24,670,000 |
| Dec 2023 | 0 | -37,064,000 | -34,101,000 | 74,374,000 | 9,479,000 | — | -32,023,000 |
| Dec 2022 | 0 | -50,188,000 | -48,588,000 | 118,375,000 | 14,968,000 | — | -39,026,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.97
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LPCN | Lipocine Inc. | $19.29M | $2.34 | — |
| APUS | Apimeds Pharmaceuticals US, Inc. | $19.77M | $1.31 | — |
| ATOS | ATOSSA THERAPEUTICS, INC. | $19.80M | $1.99 | — |
| CLRB | Cellectar Biosciences, Inc. | $19.82M | $2.48 | — |
| MDCX | Medicus Pharma Ltd. | $19.93M | $0.35 | — |
News headlines (Yahoo Finance, 1h cache)
Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer
2026-06-15 12:10 · Yahoo
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-04 20:00 · Yahoo
Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-15 11:30 · Yahoo
Sensei Biotherapeutics (SNSE): Best Performing NASDAQ Stocks According to Wall Street Analysts
2026-05-05 17:06 · Yahoo
Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer
2026-05-05 11:30 · Yahoo
Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
2026-04-09 11:30 · Yahoo
Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
2026-03-30 11:30 · Yahoo
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement
2026-02-18 13:00 · Yahoo
Egle Therapeutics Appoints John Celebi as Chief Executive Officer
2026-01-07 13:00 · Yahoo
Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results
2025-11-14 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.